The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer - PubMed (original) (raw)
. 2006 Oct;21(10):2583-92.
doi: 10.1093/humrep/del201. Epub 2006 Jul 4.
Affiliations
- PMID: 16820385
- DOI: 10.1093/humrep/del201
The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer
R A Anderson et al. Hum Reprod. 2006 Oct.
Abstract
Background: Reproductive function following cancer treatment is of increasing importance with improving survival rates. We therefore assessed the markers of the ovarian reserve in premenopausal women, to investigate and compare the effects of chemotherapy and long-term gonadotrophin withdrawal on ovarian function.
Methods: Fifty premenopausal (age range 28-52 years) women with early breast cancer were recruited. Serum hormone and ovarian ultrasound measurements were taken before treatment and at intervals up to 1 year during chemotherapy or gonadotrophin suppressive therapy.
Results: Pretreatment samples indicated a fall in anti-Müllerian hormone (AMH) concentration with age before changes in other hormone concentrations. AMH concentration showed a rapid and marked fall during chemotherapy, with undetectable concentrations in many women (P<0.0001). Inhibin B concentration showed a lesser fall (P<0.0001), whereas estradiol (E2) concentrations were maintained. Both antral follicle count (AFC) and ovarian volume fell (P<0.0001 and P<0.05 respectively). Regimens containing taxanes in addition to cyclophosphamide showed increased gonadotoxicity. Gonadotrophin suppression resulted in expected falls in E2 (P<0.05) and inhibin B (P<0.001) levels, but also resulted in a delayed fall in AMH level after 6 months (P<0.0001).
Conclusions: These data confirm the value of AMH concentration as an early indicator of ovarian ageing including assessment of chemotherapy-induced ovarian follicle loss. FSH and AMH concentration measurements may be useful for the comparison of ovarian toxicity of different chemotherapy regimens.
Similar articles
- Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial.
Wenners A, Grambach J, Koss J, Maass N, Jonat W, Schmutzler A, Mundhenke C. Wenners A, et al. BMC Cancer. 2017 Sep 6;17(1):632. doi: 10.1186/s12885-017-3593-x. BMC Cancer. 2017. PMID: 28877720 Free PMC article. - Quantifying effect of combined oral contraceptive pill on functional ovarian reserve as measured by serum anti-Müllerian hormone and small antral follicle count using three-dimensional ultrasound.
Deb S, Campbell BK, Pincott-Allen C, Clewes JS, Cumberpatch G, Raine-Fenning NJ. Deb S, et al. Ultrasound Obstet Gynecol. 2012 May;39(5):574-80. doi: 10.1002/uog.10114. Ultrasound Obstet Gynecol. 2012. PMID: 21997961 - Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer.
Anderson RA, Cameron DA. Anderson RA, et al. J Clin Endocrinol Metab. 2011 May;96(5):1336-43. doi: 10.1210/jc.2010-2582. Epub 2011 Feb 16. J Clin Endocrinol Metab. 2011. PMID: 21325458 - Anti-müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy.
Fréour T, Barrière P, Masson D. Fréour T, et al. Eur J Cancer. 2017 Mar;74:1-8. doi: 10.1016/j.ejca.2016.12.008. Epub 2017 Jan 28. Eur J Cancer. 2017. PMID: 28135602 Review. - Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients.
Bozza C, Puglisi F, Lambertini M, Osa EO, Manno M, Del Mastro L. Bozza C, et al. Endocr Relat Cancer. 2014 Jan 21;21(1):R51-65. doi: 10.1530/ERC-13-0335. Print 2014 Feb. Endocr Relat Cancer. 2014. PMID: 24292601 Review.
Cited by
- Fertility counseling of young breast cancer patients.
Lambertini M, Anserini P, Levaggi A, Poggio F, Del Mastro L. Lambertini M, et al. J Thorac Dis. 2013 Jun;5 Suppl 1(Suppl 1):S68-80. doi: 10.3978/j.issn.2072-1439.2013.05.22. J Thorac Dis. 2013. PMID: 23819030 Free PMC article. - Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors.
Su HI, Sammel MD, Green J, Velders L, Stankiewicz C, Matro J, Freeman EW, Gracia CR, DeMichele A. Su HI, et al. Cancer. 2010 Feb 1;116(3):592-9. doi: 10.1002/cncr.24746. Cancer. 2010. PMID: 19918920 Free PMC article. - Factors Associated with Unplanned Pregnancy Among Cancer Survivors.
Shandley LM, Kipling LM, Spencer JB, Morof D, Mertens AC, Howards PP. Shandley LM, et al. J Womens Health (Larchmt). 2022 May;31(5):665-674. doi: 10.1089/jwh.2021.0176. Epub 2021 Dec 2. J Womens Health (Larchmt). 2022. PMID: 34860591 Free PMC article. - Diagnostic and predictive accuracy of anti-mullerian hormone for ovarian function after chemotherapy in premenopausal women with early breast cancer.
Anderson RA, Kelsey TW, Perdrix A, Olympios N, Duhamel O, Lambertini M, Clatot F. Anderson RA, et al. Breast Cancer Res Treat. 2022 Apr;192(2):273-282. doi: 10.1007/s10549-021-06508-w. Epub 2022 Jan 8. Breast Cancer Res Treat. 2022. PMID: 34997365 Free PMC article. - Predicting Ovarian Activity in Women Affected by Early Breast Cancer: A Meta-Analysis-Based Nomogram.
Barnabei A, Strigari L, Marchetti P, Sini V, De Vecchis L, Corsello SM, Torino F. Barnabei A, et al. Oncologist. 2015 Oct;20(10):1111-8. doi: 10.1634/theoncologist.2015-0183. Epub 2015 Sep 4. Oncologist. 2015. PMID: 26341758 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical